Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
View abstract on PubMed
Summary
This summary is machine-generated.Adjuvant chemotherapy significantly benefits patients with estrogen-receptor-negative (ER-negative) breast cancer more than ER-positive breast cancer. Chemotherapy improved survival rates and reduced recurrence risk, especially for ER-negative tumors.
Area Of Science
- Oncology
- Clinical Trials
- Cancer Research
Background
- Estrogen-receptor (ER) status is crucial for predicting breast cancer treatment response.
- ER status can guide decisions regarding endocrine therapy and adjuvant chemotherapy.
Purpose Of The Study
- To compare the benefits of adjuvant chemotherapy in patients with ER-negative versus ER-positive breast tumors.
- To evaluate the impact of chemotherapy regimens on disease-free and overall survival based on ER status.
Main Methods
- Analysis of randomized trial data from the Cancer and Leukemia Group B and US Breast Cancer Intergroup.
- Comparison of patient outcomes across three distinct adjuvant chemotherapy regimens (including cyclophosphamide, doxorubicin, paclitaxel) in 6644 node-positive breast cancer patients.
- Statistical comparison of disease-free and overall survival rates stratified by ER status.
Main Results
- Chemotherapy significantly reduced recurrence risk by 55% in ER-negative tumors compared to a 26% reduction in ER-positive tumors.
- Absolute 5-year disease-free survival improvements were 22.8% for ER-negative and 7.0% for ER-positive patients.
- Overall mortality rate reductions were 55% for ER-negative and 23% for ER-positive patients, with statistically significant benefits observed only in the ER-negative group.
Conclusions
- Adjuvant chemotherapy, particularly newer regimens like biweekly doxorubicin/cyclophosphamide plus paclitaxel, offers substantial survival benefits and recurrence reduction in ER-negative breast cancer.
- The absolute benefit of adjuvant chemotherapy is considerably greater for patients with ER-negative tumors compared to those with ER-positive tumors.
- ER status is a critical factor in determining the efficacy of adjuvant chemotherapy in node-positive breast cancer patients.